Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common asthma drug help FSHD? early safety trial begins.

NCT ID NCT06721299

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times

Summary

This early-stage study is testing whether clenbuterol, a drug used for breathing problems, is safe for people with facioscapulohumeral muscular dystrophy (FSHD). About 30 adults with FSHD will receive one of three doses to see which is best tolerated. The main goal is to check for side effects like changes in heart rate, blood pressure, and lab values.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Washington

    RECRUITING

    Seattle, Washington, 98104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.